Neuland Laboratories Limited (NEULANDLAB.NS)
INR 11753.45
(7.24%)
INR 11753.45
(7.24%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 15.58 Billion INR | 30.84% |
| 2022 | 11.91 Billion INR | 28.74% |
| 2021 | 9.25 Billion INR | 0.11% |
| 2020 | 9.24 Billion INR | 21.98% |
| 2019 | 7.57 Billion INR | 17.3% |
| 2018 | 6.45 Billion INR | 25.98% |
| 2017 | 5.12 Billion INR | -10.47% |
| 2016 | 5.72 Billion INR | 12.31% |
| 2015 | 5.09 Billion INR | 9.74% |
| 2014 | 4.64 Billion INR | -0.21% |
| 2013 | 4.65 Billion INR | 1.11% |
| 2012 | 4.6 Billion INR | 2.69% |
| 2011 | 4.48 Billion INR | 13.92% |
| 2010 | 3.93 Billion INR | 41.4% |
| 2009 | 2.78 Billion INR | -9.23% |
| 2008 | 3.06 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 4.39 Billion INR | 14.18% |
| 2023 Q2 | 4.17 Billion INR | 15.08% |
| 2023 Q1 | 3.62 Billion INR | -10.83% |
| 2023 Q4 | 3.85 Billion INR | -1.99% |
| 2023 FY | 15.58 Billion INR | 30.84% |
| 2023 Q3 | 3.92 Billion INR | -5.97% |
| 2022 Q4 | 4.07 Billion INR | 51.19% |
| 2022 Q2 | 2.93 Billion INR | 32.8% |
| 2022 FY | 11.91 Billion INR | 28.74% |
| 2022 Q1 | 2.21 Billion INR | -3.88% |
| 2022 Q3 | 2.69 Billion INR | -8.33% |
| 2021 Q1 | 2 Billion INR | -13.43% |
| 2021 FY | 9.25 Billion INR | 0.11% |
| 2021 Q3 | 2.36 Billion INR | -8.29% |
| 2021 Q4 | 2.3 Billion INR | -2.69% |
| 2021 Q2 | 2.57 Billion INR | 28.35% |
| 2020 Q2 | 2.41 Billion INR | 17.51% |
| 2020 FY | 9.24 Billion INR | 21.98% |
| 2020 Q4 | 2.32 Billion INR | -5.43% |
| 2020 Q3 | 2.45 Billion INR | 1.66% |
| 2020 Q1 | 2.05 Billion INR | 10.04% |
| 2019 Q3 | 2.03 Billion INR | 9.47% |
| 2019 FY | 7.57 Billion INR | 17.3% |
| 2019 Q4 | 1.86 Billion INR | -8.42% |
| 2019 Q2 | 1.86 Billion INR | 2.88% |
| 2019 Q1 | 1.81 Billion INR | 19.24% |
| 2018 Q3 | 1.71 Billion INR | 1.62% |
| 2018 Q2 | 1.68 Billion INR | 9.6% |
| 2018 Q1 | 1.53 Billion INR | 0.0% |
| 2018 FY | 6.45 Billion INR | 25.98% |
| 2018 Q4 | 1.51 Billion INR | -11.47% |
| 2017 FY | 5.12 Billion INR | -10.47% |
| 2016 Q4 | 1.47 Billion INR | 4.35% |
| 2016 Q3 | 1.41 Billion INR | -2.12% |
| 2016 Q2 | 1.44 Billion INR | -0.4% |
| 2016 FY | 5.72 Billion INR | 12.31% |
| 2016 Q1 | 1.45 Billion INR | 0.0% |
| 2015 FY | 5.09 Billion INR | 9.74% |
| 2014 FY | 4.64 Billion INR | -0.21% |
| 2013 FY | 4.65 Billion INR | 1.11% |
| 2012 FY | 4.6 Billion INR | 2.69% |
| 2011 FY | 4.48 Billion INR | 13.92% |
| 2010 FY | 3.93 Billion INR | 41.4% |
| 2009 FY | 2.78 Billion INR | -9.23% |
| 2008 FY | 3.06 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 74.5% |
| Hester Biosciences Limited | 3.04 Billion INR | -411.772% |
| Aarti Drugs Limited | 25.28 Billion INR | 38.361% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 14.152% |
| Albert David Limited | 3.62 Billion INR | -329.999% |
| Alembic Limited | 1.57 Billion INR | -889.667% |
| Alkem Laboratories Limited | 126.67 Billion INR | 87.696% |
| Bafna Pharmaceuticals Limited | 1.52 Billion INR | -922.25% |
| Bajaj HealthCare Limited | 4.73 Billion INR | -229.219% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -3793.016% |
| Brooks Laboratories Limited | 794.86 Million INR | -1860.821% |
| Eris Lifesciences Limited | 20.09 Billion INR | 22.426% |
| FDC Limited | 19.42 Billion INR | 19.783% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 31.737% |
| Gufic Biosciences Limited | 8.06 Billion INR | -93.213% |
| Hikal Limited | 17.84 Billion INR | 12.665% |
| Ind-Swift Limited | 5.02 Billion INR | -210.185% |
| Innova Captab Limited | 10.81 Billion INR | -44.139% |
| IOL Chemicals and Pharmaceuticals Limited | 21.32 Billion INR | 26.923% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -646.797% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 76.748% |
| Lincoln Pharmaceuticals Limited | 5.8 Billion INR | -168.466% |
| Lupin Limited | 196.56 Billion INR | 92.071% |
| Mangalam Drugs & Organics Limited | 3.67 Billion INR | -324.273% |
| Medico Remedies Limited | 1.44 Billion INR | -975.471% |
| Morepen Laboratories Limited | 17.01 Billion INR | 8.421% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 7.479% |
| Orchid Pharma Limited | 8.19 Billion INR | -90.217% |
| Procter & Gamble Health Limited | 11.51 Billion INR | -35.38% |
| RPG Life Sciences Limited | 5.82 Billion INR | -167.774% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -909.623% |
| Sigachi Industries Limited | 3.98 Billion INR | -290.665% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | -25.855% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | -48.245% |
| Themis Medicare Limited | 3.81 Billion INR | -308.261% |
| Unichem Laboratories Limited | 16.57 Billion INR | 5.963% |
| Vaishali Pharma Limited | 862.79 Million INR | -1706.428% |
| Wanbury Limited | 5.75 Billion INR | -170.752% |
| Windlas Biotech Limited | 6.3 Billion INR | -147.019% |
| ZIM Laboratories Limited | 3.67 Billion INR | -324.084% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | -21.679% |
| Ipca Laboratories Limited | 77.05 Billion INR | 79.774% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 96.786% |
| Venus Remedies Limited | 5.91 Billion INR | -163.519% |
| Sakar Healthcare Limited | 1.54 Billion INR | -910.967% |
| Aurobindo Pharma Limited | 290.01 Billion INR | 94.626% |
| Divi's Laboratories Limited | 78.45 Billion INR | 80.133% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | -20.304% |
| Mankind Pharma Limited | 103.34 Billion INR | 84.919% |
| Sequent Scientific Limited | 13.69 Billion INR | -13.787% |
| Laurus Labs Limited | 50.01 Billion INR | 68.84% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.47 Billion INR | 54.793% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 86.806% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 91.806% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | -270.007% |
| Wockhardt Limited | 27.89 Billion INR | 44.117% |
| Bal Pharma Limited | 3.39 Billion INR | -359.461% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 94.417% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | -102.349% |
| Par Drugs and Chemicals Limited | 956.4 Million INR | -1529.626% |
| Caplin Point Laboratories Limited | 16.76 Billion INR | 7.049% |
| Shilpa Medicare Limited | 11.53 Billion INR | -35.164% |
| Valiant Laboratories Limited | 1.82 Billion INR | -756.094% |
| Ajanta Pharma Limited | 42.08 Billion INR | 62.968% |
| Aarey Drugs & Pharmaceuticals Limited | 3.95 Billion INR | -293.961% |
| Granules India Limited | 45.06 Billion INR | 65.414% |
| Medicamen Biotech Limited | 1.79 Billion INR | -769.228% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -501.202% |
| Piramal Enterprises Limited | 60.33 Billion INR | 74.169% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 85.304% |
| NATCO Pharma Limited | 40.02 Billion INR | 61.055% |
| Suven Life Sciences Limited | 116.92 Million INR | -13229.29% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -2991.103% |
| Strides Pharma Science Limited | 40.51 Billion INR | 61.527% |
| Indoco Remedies Limited | 18.17 Billion INR | 14.236% |
| Alpa Laboratories Limited | 1.08 Billion INR | -1333.322% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -1393.823% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -1963.107% |